News

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

News 09.09.2019 DUBLIN, IRELAND – SEPT 9, 2019 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and...

read more

Molecular Partners reports key financials for H1 19 and corporate highlights: EMA has validated the marketing authorization application for abicipar; Focus of MP0250 on multiple myeloma with expected initiation of ph2 IMiD trial in Q4 19; MP0310 ph1 start on track for H2 19

News 27.08.2019 Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA approval; MP0250 in...

read more

Clinical trial strategy: Fine-tuning the risk–reward profile

External events
Event date: 19.09.2019 1-6h30 PM, Lausanne, Sept 19th 2019  Agora Centre, CHUV University Hospital https://www.swissbiotech.org/swiss-biotech-insight-20190919/ About the event This first in a series of Swiss Biotech Insight Events will address major clinical trial strategy challenges, while exploring exciting new solutions including real world data science, adaptive clinical trial design, biomarkers and more. Join us to hear from top experts from throughout the...

read more